Author's response to reviews

Title: Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

Authors:

Benjamin Blaser (benjamin.blaser@chuv.ch)
Laurent Waselle (laurent.waselle@chuv.ch)
Anne Dormond-Meuwly (anne.meuwly-dormond@chuv.ch)
Marc Dufour (marc.dufour@chuv.ch)
Didier Roulin (Didier.roulin@chuv.ch)
Nicolas Demartines (demartines@chuv.ch)
Olivier Dormond (olivier.dormond@chuv.ch)

Version: 4 Date: 25 January 2012

Author's response to reviews: see over
Dear Editor,

Please find enclosed a revised version of our manuscript entitled “Anti-tumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells”. We are pleased to see that both reviewers appreciated the revisions that we have made and have followed their last recommendations to improve the quality of our manuscript.

**Reviewer 1:**

Minor Essential Revisions:

1) *HT29 cells have been reported to have mutated PIK3CA* (see this link, [http://www.sanger.ac.uk/perl/genetics/CGP/core_line_viewer?action=sample&id=905939](http://www.sanger.ac.uk/perl/genetics/CGP/core_line_viewer?action=sample&id=905939)). The authors may consider changing the PIK3CA mutation status of HT29 as described in page 5, line 5.

We changed the text accordingly on page 5 line 5.

2) *In Fig. 1, SW620 is still not corrected to SW480*

We apologize for this mistake and changed it in the final version.

**Reviewer 2:**

No further recommendation.

Olivier Dormond, MD-PhD
Department of Visceral Surgery
Lausanne University Hospital
Pavillon 4/Av de Beaumont
1011 Lausanne
Switzerland
phone: +41 79 556 03 40
olivier.dormond@chuv.ch

BMC Cancer
BioMed Central Ltd
236 Gray’s Inn Road
London WC1X 8HB
United Kingdom

Lausanne, January 25th 2012
We hope that you will find our revised manuscript satisfactory for publication and are looking forward to hearing from you.

Sincerely,

Olivier Dormond MD. PhD.